DDInter1214 DDInter1376
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Midostaurin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Midostaurin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Midostaurin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saxagliptin
Midostaurin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Midostaurin {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Midostaurin {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Midostaurin may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Midostaurin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Midostaurin may lead to a major life threatening interaction when taken with Leflunomide
Midostaurin may lead to a major life threatening interaction when taken with Crizotinib